Tibolone probably leads to lower vasomotor symptoms (all doses) compared with placebo (moderate certainty).
Tibolone probably leads to lower unscheduled bleeding (all doses) compared with combined HT (moderate certainty).
It is very uncertain whether tibolone changes endometrial cancer (all doses) compared with combined HT (very low certainty).
It is very uncertain whether tibolone changes breast cancer; women without previous breast cancer (all doses) compared with combined HT (very low certainty).
It is very uncertain whether tibolone changes venous thromboembolic events (clinical evaluation; all doses) compared with combined HT (very low certainty).
It is very uncertain whether tibolone changes cardiovascular events (all doses) compared with combined HT (very low certainty).
It is very uncertain whether tibolone changes cerebrovascular event (all doses) compared with combined HT (very low certainty).
It is very uncertain whether tibolone changes mortality from any cause (tibolone 2.5 mg/d) compared with combined HT (very low certainty).
It is very uncertain whether tibolone changes endometrial cancer (all doses) compared with placebo (very low certainty).
It is very uncertain whether tibolone changes breast cancer; women without previous breast cancer (all doses) compared with placebo (very low certainty).
Tibolone probably leads to higher unscheduled bleeding (all doses) compared with placebo (moderate certainty).
It is very uncertain whether tibolone changes venous thromboembolic events (clinical evaluation) all doses compared with placebo (very low certainty).
It is very uncertain whether tibolone changes cerebrovascular events (all doses) compared with placebo (very low certainty).
Tibolone showed no clear difference in mortality from any cause (all doses) compared with placebo (low certainty).
Tibolone probably leads to higher vasomotor symptoms (tibolone 2.5 mg/d) compared with combined HT (moderate certainty).